Abpro Holdings, Inc. (ABP) - Total Liabilities
Based on the latest financial reports, Abpro Holdings, Inc. (ABP) has total liabilities worth $17.30 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Abpro Holdings, Inc. (ABP) equity growth momentum to track the company's year-over-year net asset growth rate.
Abpro Holdings, Inc. - Total Liabilities Trend (2016–2024)
This chart illustrates how Abpro Holdings, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See ABP free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Abpro Holdings, Inc. Competitors by Total Liabilities
The table below lists competitors of Abpro Holdings, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
East Coast Furnitech Public Company Limited
BK:ECF
|
Thailand | ฿2.77 Billion |
|
KWG Group Holdings Limited
F:KOU
|
Germany | €140.92 Billion |
|
Planet Properindo Jaya Pt
JK:PLAN
|
Indonesia | Rp25.82 Billion |
|
Renold
LSE:RNO
|
UK | GBX211.30 Million |
|
Crest Nicholson Holdings plc
LSE:CRST
|
UK | GBX702.70 Million |
|
Playgon Games Inc
V:DEAL
|
Canada | CA$42.90 Million |
|
UTime Limited
NASDAQ:WTO
|
USA | $398.56 Million |
|
Rakovina Therapeutics Inc
V:RKV
|
Canada | CA$3.38 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Abpro Holdings, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Abpro Holdings, Inc. stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 10.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abpro Holdings, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abpro Holdings, Inc. (2016–2024)
The table below shows the annual total liabilities of Abpro Holdings, Inc. from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $19.61 Million | -77.84% |
| 2023-12-31 | $88.49 Million | +1.03% |
| 2022-12-31 | $87.59 Million | +1718.27% |
| 2021-12-31 | $4.82 Million | -87.84% |
| 2017-12-31 | $39.61 Million | +97.69% |
| 2016-12-31 | $20.03 Million | -- |
About Abpro Holdings, Inc.
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in di… Read more